Ipilimumab

Yervoy

Yervoy®

Blockade of CTLA-4, cancellation of the inhibition of T-cell activation.

01/2012

As monotherapy or in combination with nivolumab for advanced (non-resectable or metastatic) melanoma.

19% (monotherapy), 58% (combination with nivolumab);

5-year overall survival for metastatic melanoma: 26% (monotherapy), 52% (combination with nivolumab) (Larkin et al. 2019).

Ipilimumab/nivolumab or ipilimumab monotherapy:

Differential blood count, biochemical panel (sodium, potassium, chloride, calcium, phosphate, urea, creatinine, uric acid, bilirubin, ASAT, ALAT, gamma-GT, alkaline phosphatase, LDH, pancreatic amylase, total protein, CRP, CK), glucose, cortisol, TSH, fT4, high-sensitivity troponin T, troponin I, NT-pro BNP, S-100, pregnancy test, viral serologies if necessary (hepatitis B/C, HIV, CMV, EBV) ECG, echocardiography (if cardiovascular risk is present)

Ipilimumab/nivolumab or ipilimumab monotherapy:

Before each administration: differential blood count, biochemical panel (sodium, potassium, chloride, calcium, phosphate, urea, creatinine, uric acid, bilirubin, ASAT, ALAT, gamma-GT, alkaline phosphatase, LDH, pancreatic amylase, total protein, CRP, CK), glucose; every 2 months: TSH, fT4


(If necessary, initial weekly monitoring of the differential blood count and biochemical panel during combination therapy with ipilimumab/nivolumab)

3 mg/kg IV every 3 weeks for a total of 4 doses

If tolerability permits, patients should receive the full induction regime (4 doses), regardless of whether new lesions occur or existing lesions progress. The tumour response should only be assessed after completion of the induction therapy.

Refer to medical literature, guidelines, and study results.

  • Women: negative pregnancy test, dual contraception up to 120 days after the last infusion 
  • Men: adequate contraception up to 120 days after the last infusion
  • No live vaccines 30 days before starting and during therapy